WHO and biotech firms turn attention to preeclampsia, a leading cause of maternal and newborn complications

Preeclampsia, a hypertension condition that develops during pregnancy, affects millions of mothers and their newborns each year, contributing to serious health complications.

The World Health Organization has recently highlighted the disease as a priority, calling for increased research, surveillance and access to care worldwide.

A small but growing number of biopharma companies are beginning to explore therapeutic options for preeclampsia, signaling a shift after years of limited industry attention.